Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Blood (2022) 140 (21): 2248–2260.

https://doi.org/10.1182/blood.2022015478

Published: 2022

Includes: Supplemental data

Journal Articles

Ex Vivo Generation and Infusion of Anti-Minor Histocompatibility Antigen Expanded T Cells for Patients Who Relapse after Allogeneic HLA-Matched Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 1601–1603.

https://doi.org/10.1182/blood-2022-170147

Published: 2022

Journal Articles

Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)

Blood (2021) 138 (Supplement 1): 430.

https://doi.org/10.1182/blood-2021-147598

Published: 2021

Journal Articles

Decision Analysis of Allogeneic Stem Cell Transplantation for Primary Myelofibrosis

Christopher Cipkar, Srishti Kumar, Kednapa Thavorn, Natasha Kekre

Blood (2021) 138 (Supplement 1): 2923.

https://doi.org/10.1182/blood-2021-147376

Published: 2021

Journal Articles

Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Sattva S. Neelapu, Michael Dickinson, Javier Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S. Ujjani, Yi Lin, Peter A. Riedell, Natasha Kekre, Sven de Vos, Christine Lui, Francesca Milletti, Jinghui Dong, Hairong Xu, Julio C. Chavez

Blood (2021) 138 (Supplement 1): 739.

https://doi.org/10.1182/blood-2021-148009

Published: 2021

Journal Articles

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Blood (2021) 138 (3): 273–282.

https://doi.org/10.1182/blood.2021011281

Published: 2021

Journal Articles

A Systematic Review of Evidence Supporting the Use of Autologous Cell Vaccines in the Treatment of Hematological Malignancies

Donald Bastin, MSc,BSc, Sarwat Khan, MSc,BSc, Joshua Montroy, MSc, Michael A. Kennedy, PhD, Nicole Forbes, PhD, Andre B Martel, MD MSc, Laura Baker, MDM, Louise Gresham, MD, Dominique Boucher, BSc, Boaz Wong, BSc, Jean-Simon Diallo, PhD, Dean Fergusson, PhD, Manoj Lalu, MD PhD FRCPC, Rebecca C Auer, MD MSc, FRCSC, Natasha Kekre, MD MPH, FRCPC

Blood (2020) 136 (Supplement 1): 16.

https://doi.org/10.1182/blood-2020-141504

Published: 2020

Journal Articles

Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)

Sattva S. Neelapu, MD, Michael Dickinson, DMed Sci, Matthew L. Ulrickson, MD, Olalekan O. Oluwole, MBBS, MPH, Alex F. Herrera, MD, Catherine Thieblemont, MD PhD, Chaitra S. Ujjani, MD, Yi Lin, MD PhD, Peter A. Riedell, MD, Natasha Kekre, MD MPH, FRCPC, Sven de Vos, MD PhD, Yin Yang, MS, Francesca Milletti, PhD, Lovely Goyal, PhD, Jun Kawashima, MD, Julio C. Chavez, MD

Blood (2020) 136 (Supplement 1): 49.

https://doi.org/10.1182/blood-2020-134449

Published: 2020

Journal Articles

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-137221

Published: 2020

Journal Articles

Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less

Mohamad Sobh, PharmD, Lothar B. Huebsch, MD, Mitchell Sabloff, MSc,MDFRCPC, Jill Fulcher, MDPhDMRCPI FRCPath(UK), Sultan Altouri, MDFRCPC, Michael Kennah, MD, Elizabeth Drouin, MD, David S. Allan, MD FRCPC, MSc, Harold Atkins, MD, Grace Christou, MD, Pierre Villeneuve, MD PhD, Alexandre P.Blanchard, PhD, Kelsey Maclellan, Ranjeeta Mallick, PhD MSc, BSc, Nicole B. Laferriere, MD PhD, Sathish Gopalakrishnan, MD, Sita D. Bhella, MD, Natasha Kekre, MDFRCPC, Christopher Bredeson, MDFRCPC,MSc

Blood (2019) 134 (Supplement_1): 3263.

https://doi.org/10.1182/blood-2019-122436

Published: 2019

Journal Articles

Building Capacity for Relapsed/Refractory ALL Patients Needing CAR-T Cells: How Do We Prepare?

Roy Khalife, MD, Joshua Montroy, MSc, Wasithep Limvorapitak, MD, Raewyn Broady, MBChB, Dean Fergusson, PhD, Harold Atkins, MD, Robert Holt, PhD, Manoj Lalu, MD PhD FRCPC, Natasha Kekre, MD FRCPC

Blood (2018) 132 (Supplement 1): 5159.

https://doi.org/10.1182/blood-2018-99-116879

Published: 2018

Journal Articles

Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant

Blood (2018) 132 (Supplement 1): 817.

https://doi.org/10.1182/blood-2018-99-113911

Published: 2018

Journal Articles

Provincial Disparities in Access to Allogeneic Transplant in Canada

Kristjan Paulson, MD, Oliver Bucher, Geoffrey Cuvelier, MD, Andrew Daly, MD, Alina S. Gerrie, MD MPH, David Sanford, MD, David Szwajcer, MD FRCP(C), Matthew Seftel, MRCP, MD MPH, FRCPC, Irwin Walker, MBBS, Natasha Kekre, MD FRCPC, Tony H Truong, MD FRCPC, Donna Wall, MD CCPE, Kirk R. Schultz, MD, Stephen Couban, MDBSc, Christopher Bredeson, MD FRCPC, MSc

Blood (2018) 132 (Supplement 1): 4742.

https://doi.org/10.1182/blood-2018-99-113849

Published: 2018

Journal Articles

Complications and Toxicities Associated with Autologous Stem Cell Transplantation for Severe Autoimmune Diseases: Single Center Experience

Shona Philip, BSc, MSc, MD, Christopher Bredeson, MD FRCPC, MSc, David S. Allan, MD FRCPC, MSc, Sultan Altouri, MD FRCPC, Lothar B. Huebsch, MD, Harold Atkins, MD, Natasha Kekre, MD FRCPC

Blood (2018) 132 (Supplement 1): 4624.

https://doi.org/10.1182/blood-2018-99-119797

Published: 2018

Journal Articles

Phase II Trial of Natalizumab (Tysabri®) with Corticosteroids As Initial Treatment of Gastrointestinal Acute Graft Versus Host Disease

Natasha Kekre, MD FRCPC, Haesook T Kim, PhD, Vincent T Ho, MD, Yikun Guo, Umair Mahmood, Wafae Belatreche, John Koreth, MBBS, DPhil, Philippe Armand, MD PhD, Sarah Nikiforow, Edwin Alyea, III, MD, Prashant Nageshwar, MD, Brett Glotzbecker, Areej El-Jawahri, MD, Robert J. Soiffer, MD, Joseph H. Antin, MD, Yi-Bin Chen, MD, Corey S. Cutler, MD MPH

Blood (2017) 130 (Supplement 1): 3252.

https://doi.org/10.1182/blood.V130.Suppl_1.3252.3252

Published: 2017

Journal Articles

Characteristics of Venous Thromboembolism in Patients with Acute Leukemia

Yuqi Wang, MDFRCPC, Nathan Cantor, Marc Carrier, MD, Grace Christou, MD MSc, Jill Fulcher, MD PhD, Rick Ikesaka, MD, Natasha Kekre, MD FRCPC, Mitchell Sabloff, MD

Blood (2017) 130 (Supplement 1): 3869.

https://doi.org/10.1182/blood.V130.Suppl_1.3869.3869

Published: 2017

Journal Articles

Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant

Adam Bryant, MD, Ranjeeta Mallick, Lothar B. Huebsch, MD, David S. Allan, MD FRCPC, Harold Atkins, MDFRCPC, Grizel Anstee, MD, Isabelle Bence-Bruckler, MD FRCPC, Linda Hamelin, Michael Hodgins, MD, Mitchell Sabloff, MDM, Nicholas Scrivens, Dawn C. Maze, MDFRCPC,MSc, Christopher N. Bredeson, MD MSc, FRCPC, Natasha Kekre, MDMPH, FRCPC

Blood (2016) 128 (22): 5782.

https://doi.org/10.1182/blood.V128.22.5782.5782

Published: 2016

Journal Articles

Allogeneic Stem Cell Transplantation for Multiple Myeloma: a Single Center Experience

Amarilis Figueiredo, MD, Harold Atkins, MDFRCPC, Natasha Kekre, MDMPH, FRCPC, Andrea Kew, MD, Arleigh McCurdy, MD

Blood (2016) 128 (22): 5874.

https://doi.org/10.1182/blood.V128.22.5874.5874

Published: 2016

Journal Articles

Factors Influencing Long-Term Hematopoietic Function Following Autologous Stem Cell Transplantation

Alissa Visram, MD, Natasha Kekre, MD MPH, FRCPC, Christopher N. Bredeson, MD MSc, FRCPC, Jason Tay, MDFRCPC MSc, Lothar B. Huebsch, MD, Sheryl McDiarmid, Ranjeeta Mallick, PhD, Mitchell Sabloff, MDM, Harold Atkins, MDFRCPC, David S. Allan, MD FRCPC, Alan Tinmouth, MD FRCPC, Linda Hamelin, Lisa Martin, Dawn Maze, MD FRCPC MSc

Blood (2016) 128 (22): 2186.

https://doi.org/10.1182/blood.V128.22.2186.2186

Published: 2016

Journal Articles

A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

Amarilis Figueiredo, MD, Harold Atkins, MD FRCPC, Ranjeeta Mallick, PhD, Natasha Kekre, MD MPH, FRCPC, Andrea Kew, MD, Arleigh McCurdy, MD

Blood (2016) 128 (22): 4519.

https://doi.org/10.1182/blood.V128.22.4519.4519

Published: 2016

NARROW

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Ex Vivo Generation and Infusion of Anti-Minor Histocompatibility Antigen Expanded T Cells for Patients Who Relapse after Allogeneic HLA-Matched Stem Cell Transplantation

Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)

Decision Analysis of Allogeneic Stem Cell Transplantation for Primary Myelofibrosis

Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

A Systematic Review of Evidence Supporting the Use of Autologous Cell Vaccines in the Treatment of Hematological Malignancies

Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less

Building Capacity for Relapsed/Refractory ALL Patients Needing CAR-T Cells: How Do We Prepare?

Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant

Provincial Disparities in Access to Allogeneic Transplant in Canada

Complications and Toxicities Associated with Autologous Stem Cell Transplantation for Severe Autoimmune Diseases: Single Center Experience

Phase II Trial of Natalizumab (Tysabri®) with Corticosteroids As Initial Treatment of Gastrointestinal Acute Graft Versus Host Disease

Characteristics of Venous Thromboembolism in Patients with Acute Leukemia

Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant

Allogeneic Stem Cell Transplantation for Multiple Myeloma: a Single Center Experience

Factors Influencing Long-Term Hematopoietic Function Following Autologous Stem Cell Transplantation

A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only